Pages, Columns, Lines where

Figures Appear

Relevant Passages or Relevant

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Patent Number

Examiner Cite

Initial\* No

Application Number		10045674	
Filing Date		2001-10-25	
First Named Inventor	Robe	rt Ladner et al.	
Art Unit		1639	
Examiner Name	Jon D	. Epperson	
Attorney Docket Number		D2033-708931	

								i igui	сэ Аррсаі	
	1									
If you wish	n to a	ı dd additional U.S. Pater	nt citatio	n inform	ation pl	Lease click the	Add button.			
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS			
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>			Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1									
If you wish	n to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	olease click the Ad	d butto	on.	
				FOREIG	GN PAT	ENT DOCUM	ENTS			
Examiner Initial*				Kind Code4	Publication Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5	
	1	9906834	wo			1999-02-11	IXSYS Incorporate	d		
	2	9708320	wo			1997-03-06	Morphosys Gesells	chaft		
	3	0179481	wo		A2	2001-10-25	Dyax Corp.			

**U.S.PATENTS** 

Name of Patentee or Applicant

of cited Document

Kind

Code<sup>1</sup>

Issue Date

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10045674		
Filing Date		2001-10-25		
First Named Inventor	Robei	rt Ladner et al.		
Art Unit		1639		
Examiner Name	Jon D	. Epperson		
Attorney Docket Numb	or	D2033-708931		

If you wis	n to ac	dd additional Foreign Patent Document citation information please click the Add button	
		NON-PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	AUJAME et al., "High affinity human antibodies by phage display", Human Antibodies, 8(4):155-168 (1997).	
	2	BARBAS et al., "Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem," Proceedings of the National Academy of Sciences of USA, 89:4457-4461 (1992).	
	3	BALINT et al., "Antibody engineering by parsimonious mutagenesis," Gene, 1993, Vol. 137, pp. 109-118.	
	4	CORBETT et al., "Sequence of the human immunoglobulin diversity (D) segment locus: a systematic analysis provides no evidence for the use of DIR segments, inverted D segments, "minor" D segments or D-D recombination", J. Mol. Biol. 270(4): 587-597 (1997).	
	5	HOOGENBOOM et al., "Antibody phage display technology and its applications," Immunotechnology, 4(1):1-20 (1998).	
	6	JIRHOLT et al., "Exploiting sequence space: shuffling in vivo formed complementarity determining regions into a master framework," Gene, 1998, Vol. 215, No. 2, pp. 471-476.	
	7	KNAPPIK et al., "Fully Synthetic Human Combinatorial Antibody Libraries (HuCAL) Based on Modular Consensus Frameworks and CDRs Randomized with Trinucleotides", J. Mol. Biol., 296:57-86 (2000).	
	8	KRUIF et al., "Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions*, J. Mol. Biol., 248(1):97-105 (1995).	
	9	POWELL et al., "Construction, assembly and selection of combinatorial antibody libraries", pp. 155-172 in Genetic Engineering with PCR (Horton and Tait, Eds. 1998), Vol. 5 of The Current Innovations in Molecular Biology series, Horizon Scientific Press.	

## INFORMATION DISCLOSURE

 Application Number
 10045674

 Filing Date
 2001-10-25

 First Named Inventor
 Robert Ladner et al.

 Art Unit
 1639

 Examiner Name
 Jon D. Epperson

 Attorney Docket Number
 D2033-708931

(Not for submission under 37 CFR 1.99)

Art Unit

Examiner Name

J

	10	tYU et al., "Recent Progress in Biomolecular Engineering", Biotechnology Progress, 2000, Vol. 15, No. 1, pp. 2-16.
	11	isAVIRANTA et al., "Engineering the steroid-specificity of an anti-17B-estradiol Fab by random mutagenesis and ompetitive phage panning," Protein Engineering, 1998, Vol. 11, No. 2, pp. 143-152.
	12	HEETS et al., "Efficient construction of a large nonimmune phage antibody library: The production of high-affinity uman single-chain antibodies to protein antigens," Proc. Natl. Acad. Sci. USA, 1998, Vol. 95, pp. 6157-6162.
	13	sHORT et al., "Contribution of Antibody Heavy Chain CDR1 to Digoxin Binding Analyzed by Random Mutagenesis of hage-displayed Fab 26-10", Journal of Biol. Chem., Vol. 270 (1):28541-28550 (1995).
	14	ODERLIND et al., "Domain libraries: Synthetic diversity for de novo design of antibody V-regions", Gene, 1995, Vol. 60, No. 2, pp. 269-272.
	15	UCCONI et al., "Domain repertoires as a tool to derive protein recognition rules", 2000, FEBS Letters, Vol. 480, No. pp. 49-54.
If you wi	sh to a	additional non-patent literature document citation information please click the Add button
		EXAMINER SIGNATURE
Examine	r Signa	re Date Considered
*EYAMI	VER: Ir	al if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at <a href="https://www.USPTO.GOV">www.USPTO.GOV</a> or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.